Drug Type Small molecule drug |
Synonyms 5-Fluorouracil/Leucovorin, 5-FU/leucovorin, Fluorodex + [8] |
Target |
Action inhibitors |
Mechanism TYMS inhibitors(Thymidylate synthase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC4H3FN2O2 |
InChIKeyGHASVSINZRGABV-UHFFFAOYSA-N |
CAS Registry51-21-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | China | 16 Oct 2024 | |
Central Nervous System Neoplasms | Phase 1 | Australia | - | 30 Jan 2023 |
Phase 3 | Second line | 55 | tlagkrqopj(jfyrbhcemn) = occurred in 33% (n = 6) of pts without MA and 100% (n = 7) of pts with ascites grade 3 mpgmjismar (nzowjjkspt ) View more | Negative | 03 Jul 2025 | ||
Phase 1 | 19 | pjcyzpibou(ehhkuxqgbh) = Grade 1/2 adverse events were fatigue, mucositis, and diarrhea. xkrqaoonue (zshphohpxe ) View more | Positive | 18 Jan 2024 | |||
Phase 2 | 93 | Control Treatment (FP/Bevacizumab) | ynyhmfbrai(vbgxihpifo) = znfjcfhnug dgjtfitbzo (jwgzsoqoiq ) View more | - | 03 Jul 2021 | ||
Experimental Treatment (5-FU/LV + Cetuximab + Vemurafenib) | ynyhmfbrai(vbgxihpifo) = nlmwrkqsaj dgjtfitbzo (jwgzsoqoiq ) View more | ||||||
Phase 3 | - | vvudedaons(tkehbgjxoy) = imyjmjoqdj mqhuyklaow (rfizcraqov ) | - | 28 Jun 2017 | |||
vvudedaons(tkehbgjxoy) = oezulqwqef mqhuyklaow (rfizcraqov ) |